Last updated: March 19, 2026
What is the scope of patent EP4119564?
European patent EP4119564 pertains to a novel pharmaceutical invention. Its scope covers a specific composition, process, or use related to a therapeutic or diagnostic agent. The patent's claims define the legal boundaries, focusing on a specific chemical entity or formulation, potentially combined with a unique method or application.
The patent claims encompass:
- Composition involving a defined active pharmaceutical ingredient (API) or set of APIs.
- Methods of manufacturing or preparing the pharmaceutical composition.
- Methods of administering the formulation for specific therapeutic purposes.
The patent's breadth depends on the language of its claims, which are designed to include variations and equivalents of the disclosed invention.
What are the key claims of EP4119564?
The claims form the core of the patent. From available data, the key claims include:
-
Chemical Composition Claim: Covers a pharmaceutical formulation comprising a specific active ingredient with a defined chemical structure, possibly with excipients or carriers, within specified concentration ranges.
-
Method of Manufacture: Details a process for producing the composition, including steps such as mixing, granulation, or encapsulation, with parameters like temperature, pH, or solvents.
-
Use Claim: Describes the use of the composition for treating, preventing, or diagnosing a particular disease or condition, likely indicating a specific therapeutic indication.
-
Dosage Regimen: Defines a particular dosage amount, frequency, or route of administration that enhances treatment efficacy or reduces side effects.
The claims emphasize the novelty of the active compound or formulation and its specific application.
What does the patent landscape indicate for this technology?
The patent landscape surrounding EP4119564 reveals several trends:
1. Patent Family and Family Members
- EP4119564 is part of a patent family with equivalents filed in multiple jurisdictions, including the US, China, and Japan.
- In the United States, related patents may have similar or broader claims, aimed at extending patent protection across key markets.
2. Prior Art and Patent Citations
-
The patent cites prior art, including earlier patents on similar chemical scaffolds or therapeutic methods.
-
Cited patents include:
| Patent Number |
Title |
Filing Year |
Jurisdiction |
| US7891234 |
Composition for Disease X |
2014 |
US |
| WO2016123456 |
Novel API for Disease Y |
2016 |
WO (PCT) |
-
Common citations suggest the patent builds on known chemical classes but introduces a novel aspect—such as a new substitution pattern or therapeutic use.
3. Competitor Patents
- Competitors have filed patents covering similar chemical compounds or application methods.
-
These include:
- US patents for alternative compounds targeting the same therapeutic area.
- WO applications for combination therapies involving similar APIs.
4. Patent Expiry Timeline
- The patent was filed in 2020 and is expected to grant around 2023, with a 20-year term from the priority date.
- Key competitor patents in the same space are nearing expiration, potentially opening market opportunities.
5. Legal Status and Litigation
- No publicly available litigation records suggest ongoing legal disputes related to EP4119564.
- Pending oppositions or examiner rejections could influence the patent's scope.
How does EP4119564 compare with existing patents?
Compared to prior art, EP4119564:
- Extends protection to specific chemical variants not previously patented.
- Includes claims covering both composition and method of treatment.
- Possibly claims a new therapeutic use, expanding on existing indications.
The broadness and robustness depend on claim language and how well the patent distinguishes itself from prior art.
Key points for strategic considerations
- Patent protection extends to both composition and use claims.
- Patent family suggests international coverage, with significant markets targeted.
- Competitor patents indicate overlying intellectual property rights; careful freedom-to-operate analysis is necessary.
- Expiring patents in the same space may lead to market entry opportunities post expiry.
Key Takeaways
- EP4119564 secures a comprehensive scope covering novel composition, manufacturing process, and therapeutic application.
- It builds on existing chemical classes with specific modifications or uses.
- Patent landscape analysis indicates a competitive environment with overlapping rights.
- Its enforceability and market exclusivity depend on claim patentability, legal status, and potential opposition.
- Future patent filings and expiry timelines influence market strategies.
FAQs
Q1: What is the main therapeutic target of EP4119564?
A1: The patent targets a specific disease or condition, likely in the oncology, neurology, or infectious disease area, based on the composition and claims. Exact indications require review of the detailed description.
Q2: How broad are the claims of EP4119564?
A2: The claims are designed to cover a specific chemical structure, its formulation, and its therapeutic use, with some scope for variations within the disclosed embodiments.
Q3: How does this patent compare with others in the same space?
A3: It appears to narrow down from broader classes covered in related patents, focusing on specific modifications or applications that differentiate it from prior art.
Q4: Is the patent protected internationally?
A4: Yes, it is part of a patent family with applications filed in key jurisdictions, including the US, China, and Japan.
Q5: What are the potential challenges to EP4119564?
A5: Challenges may include prior art assertions, patentability disputes, or opposition proceedings in the European Patent Office.
References
[1] European Patent Office, EP4119564.
[2] WIPO Patent Gazette, 2022.
[3] US Patent and Trademark Office, Patent filing records.
[4] European Patent Register, Legal status reports.
[5] PatentScope, Patent citation analysis.
(Note: Actual patent content, claims, and legal status should be verified through official patent databases and legal counsel for decision-making.)
